Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects

BACKGROUND AND OBJECTIVES: Edoxaban is an oral, once-daily direct factor Xa inhibitor. To support the possibility that patients may choose to switch treatment from another nonvitamin K antagonist oral anticoagulant to edoxaban, this clinical study was conducted to evaluate the pharmacokinetic and ph...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Drug Investig
Hlavní autoři: Parasrampuria, Dolly A., Weilert, Doris, Maa, Jen-Fue, Dishy, Victor, Kochan, Jarema, Shi, Minggao, Brown, Karen S.
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer International Publishing 2015
Témata:
Original Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4740573/
https://ncbi.nlm.nih.gov/pubmed/26597179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40261-015-0357-8
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky